Can an immunotherapy drug replace surgery for some endometrial cancers?
⭐️ CURE ⭐️
Not yet recruiting
This phase 2 trial is testing whether the immunotherapy drug sintilimab can eliminate early-stage (I-II) MSI-H/dMMR endometrial cancer without the need for surgery. About 48 participants will receive sintilimab alone every three weeks. The goal is to see if the drug can produce a…
Phase: PHASE2 • Sponsor: Wang Jianliu • Aim: ⭐️ CURE ⭐️
Last updated Jul 30, 2026 00:00 UTC